Key result
Cardio-ankle vascular index (CAVI) was the strongest predictor of a 10-year ASCVD risk ≥10% among hypertension-mediated organ damage markers (AUC=0.736, p<.000).
Why the study?
Target organ damage and risk-enhancing factors guide treatment in borderline-to-intermediate ASCVD risk, but the comparative efficacy of HMOD markers to predict 10-year ASCVD risk ≥10% in primary hypertension was unknown.
Does the cardio-ankle vascular index (CAVI) accurately predict a 10-year ASCVD risk ≥10% in patients with primary hypertension?
Cross-Sectional (n=137)
Does the cardio-ankle vascular index (CAVI) accurately predict a 10-year ASCVD risk ≥10% in patients with primary hypertension?
CAVI is a superior surrogate marker compared to other hypertension-mediated organ damage markers for estimating ≥10% 10-year ASCVD risk in patients with primary hypertension.
Answers are grounded in this paper and cite their sources.
CAVI may refine ASCVD risk estimation in hypertension; leaves open whether it improves outcomes over standard equations.
Background: Identification of target organ damage and/or risk-enhancing factors help treatment decisions in hypertensive and hyperlipidaemic patients who reside in borderline to an intermediate risk category based on 10-year atherosclerotic cardiovascular disease (ASCVD) risk estimates.Aim: In the present study, we aimed to investigate the comparative efficacy of certain hypertension-mediated organ damage markers (HMOD) for the prediction of 10-year ASCVD risk ≥10%, in patients with primary hypertension without established CVD.Methods: One-hundred thirty-seven asymptomatic hypertensive patients ≥40 years of age were enrolled in the present study. Ten-year ASCVD risks were estimated by Pooled Cohort Equations. The following HMOD markers; pulse pressure (PP), left ventricular mass index (LVMI), carotid intima-media thickness (CIMT), ankle-brachial index (ABI), cardio-ankle vascular index (CAVI) and estimated glomerular filtration rate (eGFR) were evaluated with respect to efficacy for predicting ≥10% ASCVD risk with ROC analysis.Results: CAVI gave the greatest Area Under Curve (AUC = 0.736, p < .000), and followed by CIMT (AUC = 0.727, p < .000), LVMI (AUC = O.630, p = .01), and PP (AUC = 0.623, p = .02). ABI and eGFR were not found to be predictive. CAVI correlated best with estimated 10-year ASCVD risk (r = 0.460, p < .000). A CAVI value ≥8 was found 71% sensitive and 72% specific for predicting ≥10% risk in 10-year ASCVD risk scale. CAVI gave the best graded response to increments in 10-year ASCVD risk categories.Conclusion: We suggest that CAVI is the best surrogate for 10-year ASCVD risk, among several HMOD markers.
No takes yet. Share an insight, caveat, or question.
Ağaç et al. (2021) conducted a cross-sectional in Primary hypertension without established CVD (n=137). Cardio-ankle vascular index (CAVI) vs. Other HMOD markers (CIMT, LVMI, PP, ABI, eGFR) was evaluated on Prediction of 10-year ASCVD risk ≥10% (AUC 0.736, p=<.000). Cardio-ankle vascular index (CAVI) was the strongest predictor of a 10-year ASCVD risk ≥10% among hypertension-mediated organ damage markers (AUC=0.736, p<.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: